Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer

References

• ChengLEngCNiemanLZKapadiaASDuXLTrends in colorectal cancer incidence by anatomic site and disease stage in the United States from 1976 to 2005Am J Clin Oncol201134657358021217399
   PubMedGoogle Scholar
• SiegelRWardEBrawleyOJemalACancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deathsCA Cancer J Clin201161421223621685461
   PubMed Web of Science ®Google Scholar
• de GramontAFigerASeymourMLeucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancerJ Clin Oncol200018162938294710944126
   PubMed Web of Science ®Google Scholar
• DouillardJYCunninghamDRothADIrinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trialLancet200035592091041104710744089
   PubMed Web of Science ®Google Scholar
• GoldbergRMSargentDJMortonRFA randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancerJ Clin Oncol2004221233014665611
   PubMed Web of Science ®Google Scholar
• SaltzLBCoxJ VBlankeCIrinotecan Study GroupIrinotecan plus fluorouracil and leucovorin for metastatic colorectal cancerN Engl J Med20003431390591411006366
   PubMed Web of Science ®Google Scholar
• Van CutsemERiveraFBerrySSafety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT studyAnn Oncol200920111842184719406901
   PubMed Web of Science ®Google Scholar
• HurwitzHFehrenbacherLNovotnyWBevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancerN Engl J Med2004350232335234215175435
   PubMed Web of Science ®Google Scholar
• Van CutsemEKohneCHHitreECetuximab and chemotherapy as initial treatment for metastatic colorectal cancerN Engl J Med2009360141408141719339720
   PubMed Web of Science ®Google Scholar
• Van CutsemEKohneCHLangICetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation statusJ Clin Oncol201129152011201921502544
   PubMed Web of Science ®Google Scholar
• AmadoRGWolfMPeetersMWild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancerJ Clin Oncol200826101626163418316791
   PubMed Web of Science ®Google Scholar
• SaltzLBClarkeSDiaz-RubioEBevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III studyJ Clin Oncol200826122013201918421054
   PubMed Web of Science ®Google Scholar
• GiantonioBJCatalanoPJMeropolNJBevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200J Clin Oncol200725121539154417442997
   PubMed Web of Science ®Google Scholar
• ArnoldDAndreTBennounaJBevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: results of a randomized phase III intergroup study (TML study) [abstract]J Clin Oncol201230SupplCRA3503
   Web of Science ®Google Scholar
• GrotheyASobreroAFSienaSResults of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies [abstract]J Clin Oncol201230Suppl 4LBA385
   Web of Science ®Google Scholar
• Van CutsemETaberneroJLakomyRIntravenous (IV) aflibercept versus placebo in combination with irinotecan/5-FU (FOLFIRI) for second-line treatment of metastatic colorectal cancer (MCC): results of a multinational phase III trial (EFC10262-VELOUR) [abstract]Ann Oncol201122Suppl 5v18
   Google Scholar
• PrestaLGChenHO’ConnorSJHumanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disordersCancer Res19975720459345999377574
   PubMed Web of Science ®Google Scholar
• MulcahyMFBevacizumab in the therapy for refractory metastatic colorectal cancerBiologics200821535919707427
   PubMedGoogle Scholar
• EllisLMTakahashiYLiuWShaheenRMVascular endothelial growth factor in human colon cancer: biology and therapeutic implicationsOncologist20005Suppl 1111510804085
   PubMedGoogle Scholar
• JainRKNormalization of tumor vasculature: an emerging concept in antiangiogenic therapyScience20053075706586215637262
   PubMed Web of Science ®Google Scholar
• KimKJLiBWinerJInhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivoNature199336264238418447683111
   PubMed Web of Science ®Google Scholar
• YangJCHaworthLSherryRMA randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancerN Engl J Med2003349542743412890841
   PubMed Web of Science ®Google Scholar
• KabbinavarF FHambletonJMassRDHurwitzHIBergslandESarkarSCombined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancerJ Clin Oncol200523163706371215867200
   PubMed Web of Science ®Google Scholar
• CassidyJClarkeSDiaz-RubioERandomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancerJ Clin Oncol200826122006201218421053
   PubMed Web of Science ®Google Scholar
• MasiFLSalvatoreLCremoliniCA randomized phase III study evaluating the continuation of bevacizumab (BV) beyond progression in metastatic colorectal cancer (mCRC) patients (pts) who received BV as part of first-line treatment: results of the BEBYP trial by the Gruppo Oncologico Nord Ovest (GONO)Paper presented at: 37th ESMO ConferenceSeptember 28–October 2, 2012Vienna, Austria
   Google Scholar
• CunninghamDHumbletYSienaSCetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancerN Engl J Med2004351433734515269313
   PubMed Web of Science ®Google Scholar
• LievreASamalinEMitryEBevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective studyBMC Cancer2009934719785749
   PubMed Web of Science ®Google Scholar
• ChenHXMooneyMBoronMPhase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301J Clin Oncol200624213354336016849749
   PubMed Web of Science ®Google Scholar
• VincenziBSantiniDRussoABevacizumab in association with de Gramont 5-fluorouracil/folinic acid in patients with oxaliplatin-, irinotecan-, and cetuximab-refractory colorectal cancer: a single-center phase 2 trialCancer2009115204849485619626652
   PubMed Web of Science ®Google Scholar
• KangB WKimT WLeeJLBevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysisMed Oncol2009261323718498064
   PubMed Web of Science ®Google Scholar
• Viloria-PetitACrombetTJothySAcquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesisCancer Res200161135090510111431346
   PubMed Web of Science ®Google Scholar
• BiancoRRosaRDamianoVVascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cellsClin Cancer Res200814165069508018694994
   PubMed Web of Science ®Google Scholar
• WilhelmSMDumasJAdnaneLRegorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activityInt J Cancer2011129124525521170960
   PubMed Web of Science ®Google Scholar
• TejparSPrenenHMazzoneMOvercoming resistance to antiangiogenic therapiesOncologist20121781039105022773560
   PubMed Web of Science ®Google Scholar